Lionel Carnot
Managing Director @ Bay City Capital
Lionel Carnot is a Series B investor at Bay City Capital focused on Health Care and Biotechnology. Lionel Carnot - Partner @ Earlybird Venture Capital
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Lionel Carnot invests in
Stages Lionel Carnot invests in
Countries Lionel Carnot invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (50%)
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Pharmaceutical 2 (33%)
- Oncology 1 (17%)
Stage
- Series B 2 (33%)
- Series C 2 (33%)
- Series A 1 (17%)
Country
- Iceland 1 (17%)
- Ireland 1 (17%)
- The Netherlands 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M / Series C / May 04, 2021 | ||
| Priothera is a clinical-stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic HematopoieticStem Cell Transplantation (HSCT) in these patients. | $35.4M / Series A / Oct 12, 2020 | ||
| The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $20.5M / Series B / Jan 04, 2018 | ||
| Merus is a biotechnology company that discovers and develops new treatments for cancer patients. The company utilizes its proprietary Multiclonics Platform technology to advance its clinical pipeline of medicines. Merus conducts scientific research and clinical trials focused on developing novel treatments. | $79.1M / Series C / Apr 26, 2015 | ||
| Merus is a biotechnology company that discovers and develops new treatments for cancer patients. The company utilizes its proprietary Multiclonics Platform technology to advance its clinical pipeline of medicines. Merus conducts scientific research and clinical trials focused on developing novel treatments. | $32.9M / Series B / Oct 03, 2013 | ||
| Merus is a biotechnology company that discovers and develops new treatments for cancer patients. The company utilizes its proprietary Multiclonics Platform technology to advance its clinical pipeline of medicines. Merus conducts scientific research and clinical trials focused on developing novel treatments. | $23M / Series B / Jan 29, 2010 |
Co-Investors
About Bay City Capital
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition andagribusiness sector fund.
Bay City Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Beier
Managing Director
|
|||
Fred Gage
Scientific Advisory Board
|
|||
Fred Craves
Managing Director
|
|||
Judy Koh
Managing Director/Chief Financial Officer
|
|||
|
Lionel Carnot
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Lionel Carnot invest in?
Lionel Carnot invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 6 investments tracked by Shizune back companies in Iceland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Lionel Carnot?
Public channels for Lionel Carnot include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Lionel Carnot last invest?
The most recent investment recorded for Lionel Carnot closed in May 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
